Clinical Trial Update: Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the efficacy and safety of TAK-442 for venous thromboembolism prevention in subjects undergoing total knee replacement has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• TAK-442

Snippet

Sponsor: Takeda | Conditions: Venous Thromboembolism | Phase 2 | Status: COMPLETED